Valerio Toyos

Valerio Therapeutics is a clinical-stage biotechnology company based in Paris, France, specializing in the development of innovative oncology drugs targeting DNA Damage Response (DDR). The company's proprietary platON platform enables the design of decoy oligonucleotides that disrupt DNA repair pathways in cancer cells, effectively bypassing resistance mechanisms. Its lead candidate, AsiDNA, is a first-in-class decoy oligonucleotide currently in Phase 2 clinical trials for various solid tumors, often evaluated in combination with radiotherapy or chemotherapy. Formerly known as Onxeo, the company rebranded in 2023 to reflect its strategic focus on advanced therapeutic solutions for high-unmet-need cancers.